Cetera Trust Company N.A Takes Position in OptimizeRx Co. (NASDAQ:OPRX)

Cetera Trust Company N.A acquired a new stake in OptimizeRx Co. (NASDAQ:OPRX) in the 4th quarter, HoldingsChannel reports. The fund acquired 5,400 shares of the company’s stock, valued at approximately $77,000.

Other large investors also recently made changes to their positions in the company. AWM Investment Company Inc. lifted its holdings in OptimizeRx by 75.8% during the 3rd quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock valued at $6,088,000 after purchasing an additional 337,303 shares during the last quarter. Kennedy Capital Management LLC acquired a new stake in OptimizeRx during the 3rd quarter valued at $4,323,000. Jacob Asset Management of New York LLC lifted its holdings in OptimizeRx by 30.1% during the 3rd quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock valued at $2,881,000 after purchasing an additional 85,720 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in OptimizeRx by 3.5% during the 4th quarter. Perkins Capital Management Inc. now owns 105,463 shares of the company’s stock valued at $1,509,000 after purchasing an additional 3,600 shares during the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in OptimizeRx by 22.8% during the 3rd quarter. Los Angeles Capital Management LLC now owns 29,782 shares of the company’s stock valued at $232,000 after purchasing an additional 5,530 shares during the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Trading Down 2.5 %

Shares of NASDAQ OPRX opened at $9.09 on Tuesday. OptimizeRx Co. has a 52 week low of $6.92 and a 52 week high of $16.65. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.04 and a current ratio of 3.04. The stock’s fifty day moving average is $13.11 and its 200 day moving average is $12.04.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on OPRX shares. Barclays started coverage on OptimizeRx in a report on Wednesday, January 3rd. They set an “equal weight” rating and a $15.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. JMP Securities reiterated a “market outperform” rating and set a $15.00 price objective on shares of OptimizeRx in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price objective on shares of OptimizeRx in a research report on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.86.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.